Oncology Institute, Inc. (TOI) Gross Profit (2021 - 2026)

Oncology Institute (TOI) has 6 years of Gross Profit data on file, last reported at $147.4 million in Q1 2026.

• Quarterly Gross Profit rose 157.2% year-over-year to $147.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $375.1 million (up 38.92% YoY) and the FY2025 annual result came in at $282.2 million, up 36.62% from the prior year.
• Gross Profit climbed to $147.4 million in Q1 2026, from $22.4 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $147.4 million in Q1 2026 to a low of -$34.9 million in Q4 2023.
• A 5-year average of $59.2 million and a median of $59.8 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit jumped 455.14% — and 2023, when it plunged 205.63%.
• Tracing TOI's Gross Profit over 5 years: stood at $33.0 million in 2022, then sank by 205.63% to -$34.9 million in 2023, then soared by 256.22% to $54.5 million in 2024, then plunged by 58.85% to $22.4 million in 2025, then surged by 557.22% to $147.4 million in 2026.
• The last three Gross Profit figures came in at $147.4 million (Q1 2026), $22.4 million (Q4 2025), and $136.6 million (Q3 2025), per Business Quant data.